Jump to any asset
850 assets, updated daily
As of September 11, 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at $514.56. CleaRank Financial AI rates it Buy with a fair value of $577.50, 12.2% above the current price. Wall Street's consensus target is $577.50 across 30 analysts. RSI at 35 is in neutral territory, and the price is above its 50-day average of $510.30.
Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals Incorporated NASDAQ
$514.56
-6.560 (-1.26%)
Latest Price
AI Analyst Consensus
72 / 100
Vertex Pharmaceuticals Incorporated (VRTX) is currently trading at $514.56, above its 50-day and 200-day moving averages ($510.30 and $467.58), indicating a generally positive trend despite recent bearish momentum. The company operates within the Biotechnology sector, a field characterized by innovation and significant R&D investment. Wall Street analysts maintain a strong 'Buy' consensus, with a median price target of $577.5, suggesting an upside of 12.2% from current levels. This positive outlook is supported by projected revenue growth of 10% for the current year, reaching an estimated $13.3 billion. Despite the overall positive sentiment, significant insider selling pressure is a notable risk factor. Insiders have sold $159.2 million worth of shares against $5.8 million in purchases, signaling a 'Heavy Sell Signal' verdict. This activity warrants close monitoring, though it is key to distinguish it from potential parent divestitures or corporate restructurings. The company's strong revenue growth and analyst support provide a counterbalance to this insider selling, positioning VRTX for potential continued advancement.
VRTX Price Analysis
Market Metrics
Open
$519.13
Day Range
$514.32 to $522.60
Prev Close
$521.12
Volume
815.0K
52-Week Range
$374.17 to $560.25
Market Cap
$130.42B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Valuation is broadly in line with sector peers (0.003344% difference), suggesting fair market pricing relative to industry standards.
VRTX Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, VRTX beat estimates 2 times. However, the stock fell 2 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
VRTX Analysis
Company's Health
4/5
12-Month Analyst Target
+12.23% Upside
Median of 30 analysts (12-month)
$577.50
AI Technical Analysis
Vertex Pharmaceuticals Incorporated (VRTX) exhibits bearish momentum as indicated by its RSI of 34.86. The stock is trading below its 20-day exponential moving average of $532.21, suggesting near-term weakness, though it remains above its 50-day and 200-day moving averages ($510.30 and $467.58). Volume has been below average recently, with the latest volume at 815,000 compared to an average of 989,690. Key support levels are found at the 50-day SMA and the 200-day SMA, while resistance may be encountered near the 20-day EMA. The current technical setup suggests a cautious approach, as the bearish RSI and price action below the short-term EMA could precede further downward movement, despite the longer-term upward trend indicated by the SMAs. Investors should watch for a potential bounce from oversold conditions or a break above key resistance levels to confirm a shift in momentum.
ProTips
- Monitor insider transaction patterns closely, as the current 'Heavy Sell Signal' presents a significant risk to VRTX's stock performance.
- Given the bearish RSI momentum, consider waiting for a technical confirmation or a pullback to a stronger support level before initiating new positions.
- The company's consistent revenue growth and strong analyst backing provide a solid fundamental base, but the significant insider selling warrants a cautious approach to position sizing.
Key Catalysts
Bearish
Heavy Insider Selling Pressure
Insiders have sold $159.2 million worth of VRTX shares against only $5.8 million in purchases, triggering a 'Heavy Sell Signal' and indicating potential lack of confidence from management.
Source: Insider TransactionsBearish
Recent Earnings Miss
Vertex Pharmaceuticals missed EPS estimates in its latest reported quarter (August 3, 2026), raising concerns about near-term profitability and execution.
Source: Earnings ReportBullish
Strong Wall Street Buy Consensus
30 Wall Street analysts maintain a 'Buy' rating on VRTX, with a median price target of $577.5, suggesting a 12.2% upside from current levels.
Source: Analyst RatingsBullish
Projected Revenue Growth
Vertex Pharmaceuticals is expected to achieve 10.00% revenue growth for the current year, reaching an estimated $13.3 billion, indicating strong business expansion.
Source: Revenue EstimatesMarket Outlook
Vertex Pharmaceuticals Incorporated (VRTX) is expected to see continued growth over the next 6-12 months, supported by a strong 'Buy' consensus from Wall Street and projected revenue increases. The median analyst target price of $577.5 suggests a potential upside of 12.2% from the current price of $514.56, driven by the company's strong pipeline and market position in biotechnology. However, the significant insider selling activity, flagged as a 'Heavy Sell Signal', introduces a notable risk that could impact investor sentiment and potentially pressure the stock price. While the company's longer-term technicals remain supported by its 50-day and 200-day moving averages, the current bearish RSI momentum warrants caution. Investors should monitor upcoming earnings reports and any shifts in insider transaction patterns to gauge the sustainability of the positive outlook.
Key Statistics
| Market Cap | 130.42B |
|---|---|
| P/E Ratio | 30.02 |
| EPS (TTM) | 17.14 |
| Dividend Yield | 0.00% |
| 52 Week High | 560.25 |
| 52 Week Low | 374.17 |
Vertex Pharmaceuticals Incorporated (VRTX) trades at a P/E ratio of 30.02, which is in line with the sector average of 30.02, suggesting a fair valuation relative to its peers. The company is projected to achieve revenue growth of 10.00% for the current year, reaching approximately $13.3 billion, and is expected to grow revenue by another 9.00% next year to $14.5 billion. This consistent revenue expansion is a positive indicator for future profitability and growth. With an EPS of $17.14, VRTX demonstrates solid profitability. The company's balance sheet strength is implied by the absence of reported debt and a sector average debt-to-equity of 0.0, indicating a low-risk financial structure. The current valuation appears justified by its growth prospects and profitability, although the significant insider selling warrants careful consideration.
Earnings & Growth Analysis
Vertex Pharmaceuticals Incorporated (VRTX) recently reported mixed earnings results, missing the EPS estimate by 0.42% in its latest quarter (August 3, 2026), with actual EPS at $4.73 versus an estimate of $4.75. This followed a beat in the prior quarter where EPS was $1.17 against an estimate of $1.10, a 6.36% surprise. Prior to that, the company missed expectations by 14.29% in June 2026. Overall, the earnings trend shows inconsistency, with recent performance leaning towards misses, which could be a concern for future performance.
Key Risks
Significant insider selling presents a primary risk for Vertex Pharmaceuticals Incorporated (VRTX), with $159.2 million in sales versus $5.8 million in purchases, indicating a 'Heavy Sell Signal'. The company's recent earnings have also shown inconsistency, with a miss in the latest quarter. Also, the stock's bearish RSI momentum suggests potential for short-term price declines, despite longer-term support from moving averages.
Technical Indicators
| RSI (14) | 34.86 |
|---|---|
| MACD | 7.10 |
| SMA 50 | 510.30 |
| SMA 200 | 467.58 |
RSI
Bearish
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($510.30) above the 200-day SMA ($467.58), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.25
Weak correlation
Nasdaq 100 (QQQ)
+0.19
Weak correlation
Bitcoin (BTC)
-0.04
Weak correlation
Gold (XAU)
+0.12
Weak correlation
Check Custom Correlation
Calculating correlation...
VRTX Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
🟢 LONG ENTRY (click to switch)
CONSERVATIVE
$504.27
2% below current price (Pullback entry)
Lower risk, wait for pullback
AGGRESSIVE
$514.56
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$489.14
MAX LOSS
-3.0%
Volatility-Adjusted Stop Loss
Calculated based on RSI (34.9) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$529.48
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$554.70
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$579.91
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for VRTX is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 11, 2026.Growth of $10,000
A $10,000 investment in VRTX in September 2016 would be worth about $52,581 today, compared with about $35,030 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in VRTX today could grow to about $31,418 by 2036 in the base case, with a bull case near $118,631 and a bear case around $8,321. Projections are statistical simulations, not guarantees.
VRTX Stock Price Prediction: 2030
CleaRank's simulation projects a price near $813 for VRTX by 2030 in the base case, from $515 today (1.6x over 4 years). The downside path ends near $351. These are outcomes of a Monte Carlo simulation run on VRTX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $379 | $577 | $878 |
| 2028 | $357 | $647 | $1,172 |
| 2029 | $350 | $725 | $1,502 |
| 2030 | $351 | $813 | $1,885 |
| 2031 | $356 | $912 | $2,334 |
| 2032 | $365 | $1,023 | $2,862 |
| 2033 | $377 | $1,147 | $3,485 |
| 2034 | $392 | $1,286 | $4,220 |
| 2035 | $409 | $1,442 | $5,085 |
| 2036 | $428 | $1,617 | $6,104 |
Method: 10,000 simulated price paths using VRTX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
VRTX Insider Trading Analysis
Bought
$5.8M
2 Transactions
Sold
$159.2M
56 Transactions
Insiders
23
Active Traders
Avg Transaction
$2.8M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jul 25, 2022 | LEIDEN JEFFREY M
Officer and Director
|
Sell | 132.1K | $37.2M |
| Nov 14, 2025 | LEIDEN JEFFREY M
Officer and Director
|
Sell | 73.3K | $32.3M |
| Dec 3, 2025 | LEIDEN JEFFREY M
Officer and Director
|
Sell | 63.8K | $28.7M |
| Feb 19, 2026 | SACHDEV AMIT
Officer
|
Sell | 58.6K | $27.5M |
| May 12, 2020 | LEIDEN JEFFREY M
Officer and Director
|
Sell | 94.4K | $26.8M |
| May 5, 2020 | LEIDEN JEFFREY M
Officer and Director
|
Sell | 94.4K | $25.5M |
| May 7, 2020 | LEIDEN JEFFREY M
Officer and Director
|
Sell | 94.4K | $25.5M |
| Feb 27, 2026 | KEWALRAMANI RESHMA
Chief Executive Officer
|
Sell | 40.0K | $19.7M |
| May 5, 2020 | SACHDEV AMIT
Officer
|
Sell | 57.1K | $15.1M |
| May 7, 2020 | SACHS BRUCE I
Director
|
Sell | 45.0K | $12.1M |
Page 1 of 1
Frequently Asked Questions
Is Vertex Pharmaceuticals (VRTX) stock a buy right now?
Vertex Pharmaceuticals (VRTX) is currently rated a 'Buy' by Wall Street analysts, with a median price target of $577.5, suggesting a 12.2% upside from its current price of $514.56. The company also shows strong revenue growth projections.
What is Vertex Pharmaceuticals' (VRTX) fair value?
The fair value for Vertex Pharmaceuticals (VRTX) is estimated at $577.5, based on the median analyst price target. This represents a potential upside of 12.2% from the current trading price of $514.56.
What are the biggest risks for Vertex Pharmaceuticals (VRTX)?
The primary risks for Vertex Pharmaceuticals (VRTX) include significant insider selling totaling $159.2 million, recent inconsistent earnings performance, and bearish technical momentum indicated by its RSI.
What is Vertex Pharmaceuticals' (VRTX) revenue growth outlook?
Vertex Pharmaceuticals (VRTX) is projected to achieve revenue growth of 10.00% for the current year, with an estimated $13.3 billion in revenue, and is expected to grow revenue by another 9.00% next year to $14.5 billion.
How does Vertex Pharmaceuticals (VRTX) compare to its sector averages?
Vertex Pharmaceuticals (VRTX) trades at a P/E ratio of 30.02, which is in line with the sector average. Its projected revenue growth of 10.00% is also consistent with sector expectations.
What is the analyst consensus for Vertex Pharmaceuticals (VRTX)?
The analyst consensus for Vertex Pharmaceuticals (VRTX) is predominantly 'Buy', with 30 analysts covering the stock. This includes 5 Strong Buys, 19 Buys, 4 Holds, 1 Sell, and 1 Strong Sell, resulting in a Wall Street score of 72 out of 100.
What is Vertex Pharmaceuticals' (VRTX) stock forecast for 2030?
Based on Monte Carlo simulations, Vertex Pharmaceuticals' (VRTX) stock forecast for 2030 shows a base case price of $813.4, with a downside projection of $351.05 and an upside projection of $1884.73. These are statistical outcomes, not guaranteed price targets.